MAYNE PHARMA GROUP LIMITED — Director's Dealing 2021

Aug 1, 2021

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Mayne Pharma Group Limited
ABN	76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Scott Anthony Richards
Date of last notice	4 December 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Date of change No. of securities held prior to change Class Number acquired Number disposed Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Direct and indirect
	Solium Nominees (Australia) Pty Ltd as nominee for Scott Richards (1) HSBC Nominees (Australia) Limited as nominee for Scott Anthony Richards (2) HSBC Nominees (Australia) Limited as nominee for Scott Anthony Richards & Susan Marie Richards (3)
	31 July 2021
	28,869,697 Ordinary Shares pursuant to Executive Share Loan Scheme (1) 3,862,906 Ordinary Shares (2) 1,722,463 Ordinary Shares (3) 3,681,297 Performance Rights pursuant to Performance Right and Option Plan
	Ordinary Shares
	Nil
	2,242,005
	Not Applicable. Forfeit of employee loan shares pursuant to the Executive Share Loan Scheme

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	26,627,692 Ordinary Shares pursuant to Executive Share Loan Scheme (1) 3,862,906 Ordinary Shares (2) 1,722,463 Ordinary Shares (3) 3,681,297 Performance Rights pursuant to Performance Right and Option Plan
Nature of change Example: on-market trade, off- market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Forfeit of employee loan shares pursuant to the Executive Share Loan Scheme

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade toproceed during thisperiod?	N/a
If prior written clearance was provided, on what date was thisprovided?	N/a

• See chapter 19 for defined terms.

Appendix 3Y Page 2